We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease

This study is currently recruiting participants.
Verified July 2017 by Viking Therapeutics, Inc.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02927184
First Posted: October 6, 2016
Last Update Posted: July 19, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Viking Therapeutics, Inc.
  Purpose
This study will investigate the efficacy, safety, and tolerability of VK2809 in lowering LDL-C and liver fat content in patients with primary hypercholesterolemia and fatty liver disease. The primary efficacy endpoint is percent change from baseline LDL-C at the end of the treatment period (Week 12). Secondary endpoints include effects on liver fat content and other liver and lipid markers, as well as effects on safety and tolerability, and pharmacokinetic (PK) measurements.

Condition Intervention Phase
Hyperlipidemia NAFLD Drug: VK2809 Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess The Efficacy, Safety, and Tolerability of VK2809 Administered for 12 Weeks Followed by a 4-Week Off-Drug Phase in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease

Resource links provided by NLM:


Further study details as provided by Viking Therapeutics, Inc.:

Primary Outcome Measures:
  • Change in LDL-C in patients receiving VK2809 compared to placebo [ Time Frame: 12 weeks ]

Estimated Enrollment: 80
Study Start Date: August 2016
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: September 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Placebo capsule
Drug: Placebo
Experimental: VK2809 (5mg)
5mg VK2809 capsule
Drug: VK2809
Experimental: VK2809 (10mg)
10mg VK2809 capsule
Drug: VK2809
Experimental: VK2809 (10mg QOD)
10mg VK2809 capsule
Drug: VK2809

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Minimum of 10% liver fat as assessed by MRI - Proton Density Fat Fraction
  2. Fasting serum LDL-C >130 mg/dL at screening, >110 mg/dL on lipid lowering medications
  3. Any one of the following:

    1. Triglycerides ≥150 mg/dL or receiving prescription medication for elevated triglycerides.
    2. Systolic blood pressure >130 mmHg or diastolic blood pressure ≥85 mmHg or receiving prescription medication for hypertension.
    3. Waist circumference >40 inches (men) or >35 inches (women)
  4. Body mass index (BMI) 18.50 - 40.00 kg/m2 inclusive at screening
  5. Provide a personally-signed and dated informed consent document

Exclusion Criteria:

  1. Females of childbearing potential and males unwilling to use barrier birth control method (condom) throughout the study
  2. Resting 12-lead ECG showing QTc >450 msec, any tachyarrhythmia or morphology change, or any other clinically significant abnormality
  3. Cardiovascular event requiring hospitalization in the past year
  4. History or presence of thyroid disorder
  5. History of malignancy in past 5 years
  6. LDL-C ≥190 mg/dL or familial hypercholesterolemia
  7. Significant hepatic or renal function test abnormalities
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02927184


Contacts
Contact: Marianne Mancini 858-704-4674 mmancini@vikingtherapeutics.com

  Show 33 Study Locations
Sponsors and Collaborators
Viking Therapeutics, Inc.
Investigators
Study Director: Marianne Mancini Viking Therapeutics, Inc.
  More Information

Responsible Party: Viking Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT02927184     History of Changes
Other Study ID Numbers: VK2809-201
First Submitted: October 5, 2016
First Posted: October 6, 2016
Last Update Posted: July 19, 2017
Last Verified: July 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Liver Diseases
Hypercholesterolemia
Fatty Liver
Hyperlipidemias
Hyperlipoproteinemias
Non-alcoholic Fatty Liver Disease
Digestive System Diseases
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases